Luke Sergott
Stock Analyst at Barclays
(2.14)
# 2,712
Out of 4,712 analysts
224
Total ratings
38.46%
Success rate
-5.61%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Underweight | $145 → $135 | $135.73 | -0.53% | 6 | Nov 27, 2024 | |
| RVTY Revvity | Maintains: Overweight | $140 → $135 | $112.53 | +19.97% | 7 | Nov 25, 2024 | |
| TWST Twist Bioscience | Maintains: Overweight | $55 → $52 | $48.90 | +6.34% | 16 | Nov 19, 2024 | |
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $20 → $25 | $18.75 | +33.33% | 7 | Nov 11, 2024 | |
| CERT Certara | Maintains: Equal-Weight | $14 → $12 | $10.70 | +12.15% | 14 | Nov 7, 2024 | |
| ILMN Illumina | Maintains: Equal-Weight | $135 → $145 | $135.21 | +7.24% | 14 | Nov 5, 2024 | |
| WAT Waters | Maintains: Underweight | $330 → $360 | $372.52 | -3.36% | 16 | Nov 4, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $260 → $255 | $199.99 | +27.51% | 19 | Nov 1, 2024 | |
| TXG 10x Genomics | Maintains: Overweight | $21 → $19 | $14.67 | +29.52% | 8 | Nov 1, 2024 | |
| AVTR Avantor | Maintains: Overweight | $28 → $25 | $21.36 | +17.04% | 20 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $275 | $213.26 | +28.95% | 16 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $620 → $610 | $528.98 | +15.32% | 23 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $285 → $275 | $230.75 | +19.18% | 36 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $230 → $210 | $186.29 | +12.73% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $13.55 | +25.46% | 16 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $1.95 | +2.56% | 4 | May 10, 2024 |
Agilent Technologies
Nov 27, 2024
Maintains: Underweight
Price Target: $145 → $135
Current: $135.73
Upside: -0.53%
Revvity
Nov 25, 2024
Maintains: Overweight
Price Target: $140 → $135
Current: $112.53
Upside: +19.97%
Twist Bioscience
Nov 19, 2024
Maintains: Overweight
Price Target: $55 → $52
Current: $48.90
Upside: +6.34%
Fortrea Holdings
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $20 → $25
Current: $18.75
Upside: +33.33%
Certara
Nov 7, 2024
Maintains: Equal-Weight
Price Target: $14 → $12
Current: $10.70
Upside: +12.15%
Illumina
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $135 → $145
Current: $135.21
Upside: +7.24%
Waters
Nov 4, 2024
Maintains: Underweight
Price Target: $330 → $360
Current: $372.52
Upside: -3.36%
IQVIA Holdings
Nov 1, 2024
Maintains: Overweight
Price Target: $260 → $255
Current: $199.99
Upside: +27.51%
10x Genomics
Nov 1, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $14.67
Upside: +29.52%
Avantor
Oct 25, 2024
Maintains: Overweight
Price Target: $28 → $25
Current: $21.36
Upside: +17.04%
Oct 25, 2024
Maintains: Overweight
Price Target: $330 → $275
Current: $213.26
Upside: +28.95%
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $620 → $610
Current: $528.98
Upside: +15.32%
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $285 → $275
Current: $230.75
Upside: +19.18%
Aug 8, 2024
Maintains: Equal-Weight
Price Target: $230 → $210
Current: $186.29
Upside: +12.73%
Aug 6, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $13.55
Upside: +25.46%
May 10, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.95
Upside: +2.56%